Answers are grounded in this paper and cite their sources.
Our findings suggest use of SGLT2 inhibitors was associated with lower risk of DMO in T2DM patients in clinical practice, compared to use of GLP-1RAs. Future studies are necessary to confirm this observation.
No takes yet. Share an insight, caveat, or question.
Su et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: